These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 19234707)

  • 21. Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study.
    Di Stasi SM; Giannantoni A; Stephen RL; Capelli G; Navarra P; Massoud R; Vespasiani G
    J Urol; 2003 Sep; 170(3):777-82. PubMed ID: 12913696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Intravesical Electromotive Drug Administration®(EMDA)with Mitomycin-C for non-muscle invasive bladder cancer].
    Di Stasi SM; Dutto L; Verri C
    Urologia; 2008; 75(4):214-20. PubMed ID: 21086335
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized prospective study of intravesical prophylaxis in non-musle invasive bladder cancer at intermediate risk of recurrence: mitomycin chemotherapy vs BCG immunotherapy.
    Mangiarotti B; Trinchieri A; Del Nero A; Montanari E
    Arch Ital Urol Androl; 2008 Dec; 80(4):167-71. PubMed ID: 19235434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparison of the effectiveness between long-term instillation of mitomycin C and short-term prophylaxis with MMC or bacille Calmette-Guérin. Study of patients with non-muscle-invasive urothelial cancer of the urinary bladder].
    Isbarn H; Budäus L; Pichlmeier U; Conrad S; Huland H; Friedrich MG
    Urologe A; 2008 May; 47(5):608-15. PubMed ID: 18317718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimizing intravesical mitomycin C therapy in non-muscle-invasive bladder cancer.
    Zargar H; Aning J; Ischia J; So A; Black P
    Nat Rev Urol; 2014 Apr; 11(4):220-30. PubMed ID: 24619373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects and effectiveness of electromotive drug administration and chemohyperthermia for treating non-muscle invasive bladder cancer.
    Slater SE; Patel P; Viney R; Foster M; Porfiri E; James ND; Montgomery B; Bryan RT
    Ann R Coll Surg Engl; 2014 Sep; 96(6):415-9. PubMed ID: 25198970
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical trial of high dose hyperthermic intravesical mitomycin C for intermediate and high-risk non-muscle invasive bladder cancer during BCG shortage.
    Grimberg DC; Dudinec J; Shah A; Inman BA
    Urol Oncol; 2021 Aug; 39(8):498.e13-498.e20. PubMed ID: 33485761
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Value of an Immediate Intravesical Instillation of Mitomycin C in Patients with Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Randomised Study in 2243 patients.
    Bosschieter J; Nieuwenhuijzen JA; van Ginkel T; Vis AN; Witte B; Newling D; Beckers GMA; van Moorselaar RJA
    Eur Urol; 2018 Feb; 73(2):226-232. PubMed ID: 28705539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Electromotive drug administration with mitomycin C for intravesical treatment of non-muscle invasive transitional cell carcinoma.
    Kalsi J; Harland SJ; Feneley MR
    Expert Opin Drug Deliv; 2008 Jan; 5(1):137-45. PubMed ID: 18095933
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly bacillus Calmette-Guérin (BCG) or alternating BCG and interferon-α2b instillations: prospective randomised FinnBladder-4 study.
    Järvinen R; Marttila T; Kaasinen E; Rintala E; Aaltomaa S; Kallio J; Liukkonen T; Puolakka VM; Seppänen M; Tuhkanen K; Vaarala M; Viitanen J; Boström PJ;
    Eur Urol; 2015 Oct; 68(4):611-7. PubMed ID: 25748117
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chemoablation with Intensive Intravesical Mitomycin C Treatment: A New Approach for Non-muscle-invasive Bladder Cancer.
    Racioppi M; Di Gianfrancesco L; Ragonese M; Palermo G; Sacco E; Bassi P
    Eur Urol Oncol; 2019 Sep; 2(5):576-583. PubMed ID: 31411974
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review.
    Carando R; Pradere B; Afferi L; Marra G; Aziz A; Roghmann F; Krajewski W; Di Bona C; Alvarez-Maestro M; Pagliarulo V; Xylinas E; Moschini M
    Prog Urol; 2020 May; 30(6):322-331. PubMed ID: 32279953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chemohyperthermia using MMC in non-muscle-invasive bladder cancer: Current status and future perspectives.].
    Coenen JJMJH; van Valenberg FJP; Arends TJH; Witjes JA
    Arch Esp Urol; 2018 May; 71(4):400-408. PubMed ID: 29745929
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer.
    Melgarejo Segura MT; Morales Martínez A; Yáñez Castillo Y; Arrabal Polo MÁ; Gutiérrez Tejero F; Pareja Vílchez M; Arrabal Martín M
    Bladder Cancer; 2023; 9(2):159-166. PubMed ID: 38993293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single early instillation of mitomycin C and urinary alkalinization in low-risk non-muscle-invasive bladder cancer: a preliminary study.
    Ersoy H; Yaytokgil M; Karakoyunlu AN; Topaloglu H; Sagnak L; Ozok HU
    Drug Des Devel Ther; 2013; 7():1-6. PubMed ID: 23300343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial.
    Li R; Li Y; Song J; Gao K; Chen K; Yang X; Ding Y; Ma X; Wang Y; Li W; Wang Y; Wang Z; Dong Z
    BMC Urol; 2020 Jul; 20(1):97. PubMed ID: 32660456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Assessment of the optimization of the conditions of mitomycin C intravesical instillation completion in the setting of non-muscle invasive bladder cancer treatment].
    Lailler G; Neuzillet Y; Rouanne M; Lebret T
    Prog Urol; 2016 Feb; 26(2):79-82. PubMed ID: 26653577
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Sequential treatment with Mitomycin C and BCG in non muscle invasive bladder cancer.].
    Chantada-Abal V; Chantada-Tirado C; Lamas-Díaz L; Caramés-Masana F; Villegas-Piguave AD; Villar-Vázquez N
    Arch Esp Urol; 2018 May; 71(4):453-457. PubMed ID: 29745935
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis.
    Zhou W; Liu J; Mao D; Hu C; Gao D
    PLoS One; 2022; 17(10):e0276453. PubMed ID: 36269742
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study.
    Colombo R; Rocchini L; Suardi N; Benigni F; Colciago G; Bettiga A; Pellucchi F; Maccagnano C; Briganti A; Salonia A; Rigatti P; Montorsi F
    Eur Urol; 2012 Nov; 62(5):797-802. PubMed ID: 22633362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.